全文获取类型
收费全文 | 888篇 |
免费 | 55篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 20篇 |
妇产科学 | 20篇 |
基础医学 | 112篇 |
口腔科学 | 22篇 |
临床医学 | 70篇 |
内科学 | 165篇 |
皮肤病学 | 19篇 |
神经病学 | 69篇 |
特种医学 | 16篇 |
外科学 | 99篇 |
综合类 | 10篇 |
预防医学 | 77篇 |
眼科学 | 119篇 |
药学 | 81篇 |
中国医学 | 10篇 |
肿瘤学 | 34篇 |
出版年
2023年 | 6篇 |
2022年 | 21篇 |
2021年 | 22篇 |
2020年 | 12篇 |
2019年 | 31篇 |
2018年 | 26篇 |
2017年 | 19篇 |
2016年 | 42篇 |
2015年 | 35篇 |
2014年 | 41篇 |
2013年 | 50篇 |
2012年 | 64篇 |
2011年 | 89篇 |
2010年 | 36篇 |
2009年 | 28篇 |
2008年 | 59篇 |
2007年 | 71篇 |
2006年 | 42篇 |
2005年 | 49篇 |
2004年 | 43篇 |
2003年 | 45篇 |
2002年 | 34篇 |
2001年 | 6篇 |
2000年 | 6篇 |
1999年 | 8篇 |
1998年 | 2篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 9篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有946条查询结果,搜索用时 359 毫秒
941.
Besides the receptor-mediated effects of pioglitazone, the involvement of nitric oxide (NO) has been previously demonstrated in some pioglitazone-induced central and peripheral effects. In the present study, the effects of acutely administered pioglitazone on pentylenetetrazole (PTZ)-induced seizures and involvement of NO were evaluated in mice. To determine the threshold for clonic seizures, PTZ was administered intravenously. A single dose of pioglitazone (10, 20, 40 and 80 mg/kg, p.o.) was administered either 2 or 4h prior to induction of seizures. For determination of possible role of peroxisome proliferator activated receptor gamma (PPAR-γ) and nitric oxide pathway in this effect, the effects of a PPAR-γ antagonist, GW9662 (2 mg/kg); a non-specific nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine methyl ester (L-NAME; 0.3, 1, 3, and 10 mg/kg); a specific iNOS inhibitor, aminoguanidine (100mg/kg, i.p.) or a nitric oxide precursor, L-arginine (30, 60, 100 and 200mg/kg, i.p.); each administered 15 min prior to pioglitazone, were investigated on the anticonvulsant effect of this drug. Administration of pioglitazone (40 and 80 mg/kg) increased the threshold of PTZ-induced seizure in a dose-dependent, and time-dependent manner. GW9662 reversed the anticonvulsant effect of pioglitazone (40 mg/kg). Acute administration of L-NAME (1, 3 and 10mg/kg) inhibited the anticonvulsant effect of pioglitazone (40 mg/kg), the same result was detected with aminoguanidine (100mg/kg); whereas L-arginine, in the noneffective dose (100mg/kg), potentiated the seizure threshold when co-administered with a subeffective dose of pioglitazone (20mg/kg). CONCLUSION: The present study demonstrates the anticonvulsant effect of acute pioglitazone on PTZ-induced seizures in mice. This effect was reversed by PPAR-γ antagonist, and both a specific- and a non-specific nitric oxide synthase inhibitors, and augmented by nitric oxide precursor, L-arginine. These results support that the anticonvulsant effect of pioglitazone is mediated through PPAR-γ receptor-mediated pathway and also, at least partly, through the nitric oxide pathway. 相似文献
942.
Resul Kahraman Abdurrahman ahin Ouzhan
ztürk Turan alhan Süleyman Sayar Evren Kanat Levent Doanay Kamil
zdil 《The Turkish journal of gastroenterology》2022,33(1):35
BackgroundWe aimed to investigate the long-term effects of tenofovir disoproxil fumarate and entecavir treatment on bone mineral density and evaluated the fracture risk assessment tool score in patients with chronic hepatitis B.MethodsA total of 58 chronic hepatitis B patients treated with tenofovir disoproxil fumarate (n = 40) and entecavir (n = 18) were included in this prospective study from 2012 to 2016. To evaluate bone mineral density, dual-X-ray absorptiometry, fracture risk assessment tool, and laboratory examinations were performed in all patients first at baseline and second at the end of the study.ResultsAge, sex, body mass index, fibrosis score, and viral load were similar in both groups. The mean follow-up was 33 months in the tenofovir disoproxil fumarate group and 31 months in the entecavir group. In patients treated with entecavir, there was no statistically significant difference between baseline and second bone mineral density including lumbar spine (L) and total hip T score. In patients treated with tenofovir disoproxil fumarate, there was a significant difference in the second bone mineral density compared with baseline bone mineral density for L3 (P = .033) and the major fracture risk assessment tool score (P = .03). When patients were divided into 3 groups (normal bone mineral density, osteopenic, and osteoporotic), there was a significant increase in the number of osteopenic patients in the total hip T score after tenofovir disoproxil fumarate treatment (P = .034).ConclusionOur results suggest a decrease in the bone mineral density for lumbar spine (L3), an increase in the number of patients with hip osteopenia, and major fracture risk assessment tool score after long-term tenofovir disoproxil fumarate treatment in patients with rechronic hepatitis B. 相似文献
943.
Effects of Supplementation with Heracleum persicum Fruit Extract on Serum Lipids in Patients Undergoing Coronary Angiography: A Pilot Trial
下载免费PDF全文
![点击此处可从《Phytotherapy research : PTR》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Yahya Dadjo Yunes Panahi Bahram Pishgoo Amirhossein Sahebkar Hamidreza Taghipour Ahmad Akbari Shahram Parvin 《Phytotherapy research : PTR》2015,29(1):141-143
Heracleum persicum Desf. Ex Fischer (Apiaceae) is a native medicinal plant in the Iranian traditional medicine and also a safe and common dietary spice. The present pilot study aimed to investigate the impact of supplementation with H. persicum fruits on serum lipid concentrations in a group of patients with minimal coronary artery disease. Subjects who were diagnosed with <50% luminal narrowing in any of the major coronary arteries in coronary angiography were recruited for this trial and were randomized to receive either H. persicum hydroalcoholic fruit extract (n = 15; 300 mg/day) or placebo (n = 12) for a period of 6 months. Serum concentrations of total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, and triglycerides were measured at baseline and at the end of study. No significant difference in concentrations of total cholesterol, low‐density lipoprotein cholesterol, and high‐density lipoprotein cholesterol was observed between H. persicum extract and placebo groups (p > 0.05). However, serum triglycerides levels were reduced after H. persicum extract supplementation in a borderline significant manner (p = 0.063). Short‐term supplementation with H. persicum fruit extract might be used as an adjunctive treatment for patients with hypertriglyceridemia. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
944.
945.
946.